All Comparisons
Cerebrolysin vs PE-22-28
Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.
Cerebrolysin: CPE-22-28: D
| Attribute | Cerebrolysin | PE-22-28 |
|---|---|---|
| Category | Nootropic / Neuroprotective | Nootropic / Neuroprotective |
| Evidence Rating | C — Phase I–II Clinical Trials | D — Preclinical Only |
| Clinical Status | Approved as prescription drug in 50+ countries (Austria, Russia, China, South Korea, and others). Not FDA-approved. Over 150 clinical trials with >7,000 patients. | Preclinical tool compound only. No clinical trials. No regulatory evaluation. |
| Mechanism | Cerebrolysin provides multimodal neuroprotection through several pathways: it enhances neurogenesis and neuroplasticity via activation of PI3K/AKT and Sonic Hedgehog (Shh) signaling, promotes synaptic remodeling through CREB phosphorylation and BDNF-like activity, inhibits calpain-mediated neuronal ... | PE-22-28 blocks the TREK-1 two-pore-domain potassium channel (KCNK2/K2P2.1), which is widely expressed in the brain. TREK-1 knockout mice display a depression-resistant phenotype, suggesting that TREK-1 blockade may have antidepressant effects. PE-22-28 is a more potent and shorter analog of spadin ... |
| Half-Life | Not meaningfully defined for a multi-component preparation | Improved over spadin in rodent work; not established in humans |
| Bioavailability | Given by intravenous or intramuscular injection; not orally active | — |
| Molecular Weight | Heterogeneous mixture, peptide fraction below ~10,000 g/mol | ~800 to 900 g/mol |
| WADA Status | Not Listed | Not Listed |
| Research Half-Life | Not meaningfully defined for a multi-component preparation | Improved over spadin in rodent work; not established in humans |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | Not FDA-approved. No IND application. Cannot be legally prescribed. | Not FDA-evaluated. Research tool compound. Sold by some peptide suppliers as a research chemical. |
Research Material Specifications
Catalog specifications for the corresponding research materials, including batch documentation coverage.
| Specification | Cerebrolysin | PE-22-28 |
|---|---|---|
| Purity Standard | >99% | >99% |
| CAS Number | — | — |
| Molecular Formula | — | — |
| Available Formats | 60mg | 10mg |
| Batch COAs Published | — | — |
| Stock Status | Out of stock | Out of stock |
Availability at Volta Peptides
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.